Disease · MONDO_0005298
Comparisons in its trials113
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 113
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With a Composite Endpoint of Nonfatal MI, Nonfatal Stroke, Heart Failure or In-hospital Cardiovascular Death | 495 of 11,027 | 471 of 11,027 | 22,054 | NCT04974723 | Trial comparisons |
| Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With a Nonvertebral Fracture | 313 of 11,027 | 333 of 11,027 | 22,054 | NCT04974723 | Trial comparisons |
| Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With Hip Fracture | 112 of 11,027 | 125 of 11,027 | 22,054 | NCT04974723 | Trial comparisons |
| Patients Treated With ABL vs Patients Treated With TPTD: deaths from any cause | 10 of 11,027 | 9 of 11,027 | 22,054 | NCT04974723 | Trial comparisons |
| Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With Composite Endpoint of Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or In-hospital Cardiovascular Death | 221 of 11,027 | 211 of 11,027 | 22,054 | NCT04974723 | Trial comparisons |
| Denosumab 60 mg Q6M vs Placebo: Number of Participants With Nonvertebral Fractures | 238 of 3,902 | 293 of 3,906 | 7,808 | NCT00089791 | Trial comparisons |
| Denosumab 60 mg Q6M vs Placebo: Number of Participants With a Hip Fracture | 26 of 3,902 | 43 of 3,906 | 7,808 | NCT00089791 | Trial comparisons |
| Denosumab 60 mg Q6M vs Placebo: serious adverse events | 1,004 of 3,886 | 972 of 3,876 | 7,762 | NCT00089791 | Trial comparisons |
| Denosumab 60 mg Q6M vs Placebo: Number of Participants With New Vertebral Fractures | 86 of 3,702 | 264 of 3,691 | 7,393 | NCT00089791 | Trial comparisons |
| Placebo (Core+SE I+SE II) vs Bazedoxifene 20 mg (SE II): Number of Participants With Worsening Vertebral Fractures Through Month 84 | 1 of 1,741 | 7 of 3,410 | 5,151 | NCT00205777 | Trial comparisons |
| SMC021 vs Placebo: Number of Patients With Non-vertebral Fractures | 75 of 2,334 | 82 of 2,331 | 4,665 | NCT00525798 | Trial comparisons |
| SMC021 vs Placebo: serious adverse events | 340 of 2,334 | 378 of 2,331 | 4,665 | NCT00525798 | Trial comparisons |
| Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With Non-Vertebral Fractures | 172 of 2,343 | 219 of 2,207 | 4,550 | NCT00523341 | Trial comparisons |
| Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With Antibodies to Denosumab | 0 of 2,343 | 1 of 2,206 | 4,549 | NCT00523341 | Trial comparisons |
| Denosumab/ Denosumab 60 mg Q6M vs Placebo/ Denosumab 60 mg Q6M: serious adverse events | 1,014 of 2,343 | 945 of 2,206 | 4,549 | NCT00523341 | Trial comparisons |
| SMC021 vs Placebo: Number of Patients With New Vertebral Fractures | 94 of 2,064 | 99 of 2,125 | 4,189 | NCT00525798 | Trial comparisons |
| Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With New Vertebral Fractures | 149 of 2,116 | 145 of 1,991 | 4,107 | NCT00523341 | Trial comparisons |
| 5 mg Risedronate vs 150 mg Risedronate: Number of Participants With New Vertebral Fracture at Month 12, ITT Population | 8 of 642 | 8 of 650 | 1,292 | NCT00247273 | Trial comparisons |
| 5 mg Risedronate vs 150 mg Risedronate: Number of Participants With New Vertebral Fracture at Month 24, ITT Population | 14 of 642 | 14 of 650 | 1,292 | NCT00247273 | Trial comparisons |
| 5 mg Risedronate vs 150 mg Risedronate: serious adverse events | 51 of 642 | 77 of 650 | 1,292 | NCT00247273 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005298/comparisons